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BACKGROUND: Pediatric patients with atrioventricular valve disease 
have limited options for prosthetic valve replacement in sizes <15 mm. 
Based on successful experience with the stented bovine jugular vein 
graft (Melody valve) in the right ventricular outflow tract, the prosthesis 
has been modified for surgical valve replacement in pediatric patients 
with atrioventricular dysfunction with the intention of subsequent valve 
expansion in the catheterization laboratory as the child grows.
METHODS AND RESULTS: A multicenter, retrospective cohort study 
was performed among patients who underwent atrioventricular valve 
replacement with Melody valve at 17 participating sites from North 
America and Europe, including 68 patients with either mitral (n=59) or 
tricuspid (n=9) replacement at a median age of 8 months (range, 3 days to 
13 years). The median size at implantation was 14 mm (range, 9–24 mm). 
Immediately postoperatively, the valve was competent with low gradients 
in all patients. Fifteen patients died; 3 patients underwent transplantation. 
Nineteen patients required reoperation for adverse outcomes, including 
valve explantation (n=16), left ventricular outflow tract obstruction (n=1), 
permanent pacemaker implantation (n=1), and paravalvular leak repair 
(n=1). Twenty-five patients underwent 41 episodes of catheter-based 
balloon expansion, exhibiting a significant decrease in median gradient 
(P<0.001) with no significant increase in grade of regurgitation. Twelve 
months after implantation, cumulative incidence analysis indicated that 
55% of the patients would be expected to be free from death, heart 
transplantation, structural valve deterioration, or valve replacement.
CONCLUSIONS: The Melody valve is a feasible option for surgical 
atrioventricular valve replacement in patients with hypoplastic annuli. 
The prosthesis shows acceptable short-term function and is amenable to 
catheter-based enlargement as the child grows. However, patients remain 
at risk for mortality and structural valve deterioration, despite adequate 
early valvular function. Device design and implantation techniques must 
be refined to reduce complications and extend durability.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT02505074.
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Clinical and surgical management of atrioven-tricular valve disease in infants and young chil-dren remains a therapeutic challenge with high 
morbidity and mortality associated with valve replace-
ment.1–3 Mitral valve replacement (MVR), in particular, 
has proven to be challenging in this population with 
relatively high rates of reintervention.2,4–11 A unique 
challenge is the lack of commercially available pros-
thetic valve replacement options for children with 
annuli <15 mm.
In the past decades, the development of new valve 
technologies has made the percutaneous replacement 
of dysfunctional valves possible.12,13 The Melody valve 
(Medtronic, Minneapolis, MN) is a stent-mounted valved 
bovine jugular vein graft that is approved for transcath-
eter implantation into the right ventricular outflow tract 
position where it has been shown to restore pulmonary 
valve competence and relieve outflow tract obstruction, 
even in young patients.14
Based on its favorable design characteristics and ini-
tial success in the right ventricular outflow tract posi-
tion, the Melody valve was adapted for atrioventricular 
valve replacement. Initial experience demonstrated the 
feasibility of MVR with the Melody valve in patients 
with annuli <15 mm.15–18 Importantly, these studies 
demonstrated the valve could be expanded in the cath-
eterization laboratory after somatic growth, thus avoid-
ing early reoperation.
Following the initial studies, an increasing num-
ber of centers began offering Melody valve for atrio-
ventricular replacement. Given the rarity of suitable 
cases, an international multicenter registry of atrio-
ventricular valve replacement with the Melody valve 
was established in North America and Europe to allow 
for rapid accumulation of combined experience rather 
than a single-center effort. Thus, in the present study, 
we aim to report the current multicenter experience 
with Melody valve in atrioventricular position and to 
investigate the procedural short- and medium-term 
outcomes.
METHODS
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure.
Study Design and Patient Selection
A multicenter, retrospective cohort study was performed 
among patients who underwent atrioventricular valve replace-
ment with the Melody valve in 17 pediatric cardiac programs 
in North America and Europe. Approval was obtained from 
the institutional review board at each center, with either 
waiver of informed consent or written consent obtained 
before data collection. Insertion of the Melody valve in the 
mitral and tricuspid positions was performed under off-label 
use designation in all centers.
Candidates for surgical Melody insertion typically included 
patients with annuli <15 mm, which is deemed too small 
for implantation of a traditional mechanical or bioprosthetic 
valve. Deidentified clinical and echocardiographic data, from 
the time of diagnosis until the most recent follow-up (if appli-
cable), were sent to the lead site at Boston Children’s Hospital 
for collection and analysis.
Data Collection
Collected data included basic demographic information, 
descriptive anatomic diagnoses, associated noncardiac or 
genetic anomalies, preoperative factors, surgical procedures 
performed, complications incurred at the time of surgery or 
during follow-up, and mortality. Procedural details, including 
valve modification and insertion techniques, were collected 
from operative reports.
Data collected from follow-up included gradient and 
degree of valvular regurgitation immediately after implan-
tation, at hospital discharge, and at most recent follow-up. 
Performance of the Melody valve was assessed based on 
freedom from structural valve deterioration (SVD) defined 
as regurgitation classified as moderate or greater on echo-
cardiography. The study was unable to discriminate between 
central regurgitation and regurgitation because of paravalvu-
lar leaks or stent fracture. Progressive development of trans-
valvular stenosis was not included within definition of SVD as 
increasing gradient with somatic growth was anticipated and 
prompted transcatheter valve expansion. For patients who 
underwent catheter-based expansion of the Melody valve, 
the time to first cardiac catheterization, interval between dila-
tions, and total number of interventions for valve expansion 
were documented.
Outcomes
The primary outcomes evaluated were1 SVD and valve replace-
ment, and2 mortality or orthotopic heart transplantation 
(OHT). An additional outcome limited to descriptive analyses 
included surgery for procedure-related complications.
WHAT IS KNOWN
• An externally stented bovine jugular vein graft is an 
expandable valve currently offered as an option for 
replacement of the right ventricular outflow tract.
• There are limited options for bioprosthetic valves in 
pediatric patients with atrioventricular valve annuli 
<15 mm.
WHAT THE STUDY ADDS
• The surgically modified and implanted externally 
stented bovine jugular vein graft offers acceptable 
short-term function in the atrioventricular valve 
position in pediatric patients.
• In addition, the surgically implanted externally 
stented bovine jugular vein graft is amenable to 
catheter-based expansion as the child grows.
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Operative Procedure
For atrioventricular valve replacement, the technique for 
implantation has been described previously.15–20 In most of 
the patients, a circumferential skirt of bovine pericardium 
was sewn externally to the stent at its midsection to facilitate 
fixation to the valve annulus. The circumferential skirt was 
sutured to the annulus with either interrupted or continuous 
sutures. After annular fixation, balloon dilation of the valve 
was performed (Figure 1). The balloon size was generally 1 
mm greater than the anteroposterior valve annular measure-
ment obtained by preoperative transthoracic or transesoph-
ageal echocardiography, as confirmed intraoperatively by 
ensuring passage of a similar-sized Hegar dilator through the 
annulus. Echocardiography was performed before discharge 
and at routine intervals to evaluate the progression of trans-
valvular gradient and regurgitation. Details of surgical proce-
dure and prosthesis modifications were collected.
Catheter-Based Valve Expansion
A patient was deemed a candidate for re-expansion if the 
mean gradient across the prosthesis as measured by pulse 
wave Doppler increased with somatic growth to >10 mm Hg. 
At catheterization, femoral or jugular venous access was used 
to approach the valve. For mitral dilation, the left atrium was 
accessed through either a previously placed atrial septal defect 
or transseptal puncture (Figure 1F). The balloon size used for 
expansion was recorded and compared with the original bal-
loon size used at implantation. Gradients across the prosthe-
sis and regurgitation grade were recorded immediately before 
and after catheter-based expansion.
Statistical Analysis
Categorical variables are presented as proportions and con-
tinuous variables as mean±SD or median (interquartile range, 
minimum to maximum) as appropriate.
The median postoperative gradient and amount of regur-
gitation before and after balloon dilation were compared 
by nonparametric Wilcoxon signed-rank test and McNemar 
paired test, respectively. Overall mortality or OHT was ana-
lyzed using the Kaplan-Meier method.
Analysis of the cardiac catheterization data was conducted 
accounting for death or OHT as competing event.21 A further 
competing risks analysis was conducted on the first occur-
rence, during follow-up of SVD or valve explantation, and 
death or OHT. Gray test was used to evaluate hypotheses of no 
difference of crude cumulative incidence functions between 
different techniques of valve modification and implantation, 
primary diagnosis, and quartiles of age at the time of surgery.
Median follow-up time was calculated according to 
reverse Kaplan-Meier method.22
Statistical analysis was performed using SAS 9.4 (SAS 
Institute, Cary, NC). A 2-tailed P ≤0.05 was considered statis-
tically significant.
RESULTS
The study enrolled 68 patients who underwent surgical 
implantation of an expandable bovine jugular vein valve 
into mitral (n=59) or tricuspid (n=9) positions. Patient 
characteristics are outlined in Table 1.
The majority of patients were males (57%) with a 
median age at implantation of 8.6 months (range, 3 days 
to 14 years). Two patients were >8 years of age at the 
time of Melody valve implantation. In 1 case, the patient 
was unusually small for age (age, 12 years; weight, 7.8 
kg) with a mitral valve annulus of only 12 mm. Similarly, 
in the second case, the patient had a diagnosis of Shone 
complex, and the mitral valve annulus was deemed too 
small for any available prosthesis. Indications for valve 
replacement included valvular regurgitation moderate or 
greater in 17 (mitral, n=11; tricuspid, n=6), valvular ste-
nosis (moderate or greater) in 7 (mitral, n=5; tricuspid, 
n=2), and both regurgitation and stenosis in 44 (mitral, 
n=43; tricuspid, n=1) patients. Eleven (16%) patients had 
associated comorbidities, primarily genetic syndromes.
Figure 1. Steps of Melody valve preparation, surgical implantation, and intraoperative catheter balloon dilation.  
A-C, Preparation of the valve; (D-E) implantation of the valve; (F) catheter balloon dilation of the Melody valve during follow up. Reprinted from Frigiola et al26 with 
permission. Copyright ©2017, Europa Digital & Publishing. 
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Gray test showed no difference of crude cumula-
tive incidence functions (SVD or valve replacement and 
mortality or OHT) and age at the time of surgery or 
primary diagnosis (P=0.958 and P=0.724, respectively).
Most patients (72%) had undergone at least 1 
previous surgical attempt to repair the dysfunctional 
atrioventricular valve, and 28% of the patients had >1 
surgical valve revision before undergoing Melody valve 
implantation. Six (9%) patients had prosthetic valve dys-
function as indication for Melody valve implantation.
Procedural details, including valve modification and 
insertion techniques, are outlined in Table 2. In all but 6 
patients, the Melody valve was modified before implan-
tation. In 48 patients (mitral, n=41; tricuspid n=7), the 
valve was shortened by trimming or folding of the prox-
imal or distal crowns.19 In 13 (22%) patients with the 
Melody valve in mitral position, the prosthesis was fur-
ther shortened before implantation by creating a deep 
V-shaped incision on the side facing the left ventricular 
outflow tract (LVOT) to prevent additional obstruction of 
the outflow. In 42 cases (mitral, n=38; tricuspid, n=4), 
a strip of pericardium was sutured around the exterior 
stent valve in a skirt to facilitate anchoring to the valve 
annulus. Fixation of the distal stent to the posterior wall 
of the left ventricle to prevent excessive device motion 
during the physiological annular systolic motion was 
performed in 21 patients who implanted the Melody 
valve in mitral position. The atrial septum, removed to 
allow access to the mitral valve from right atriotomy, was 
reconstructed with patch material and fenestrated to 
allow future catheter access to the prosthesis in 17 cases. 
Once sutured to the native valve annulus, the Melody 
valve was expanded with a balloon catheter to reach the 
desired diameter. The balloon size utilized for initial valve 
expansion was a median of 14 mm (range, 9–24 mm).
Nine (13%) patients developed various degrees of 
transient heart block immediately after implantation, 
including 8 patients who underwent MVR and 1 who 
underwent tricuspid valve replacement. Permanent 
pacemaker was documented only in 1 patient. One 
patient with hypoplastic left heart syndrome under-
went pacemaker implantation at time of Melody valve 
implantation for preexisting complete heart block.
Table 1. Demographic Data for n=68 Patients
Characteristics Value
Age at diagnosis, mo; median (IQR) 8.6 (17.52)
Men, n (%) 39 (57)
Weight, kg; median (IQR) 6.6 (5.27)
BSA, m2; median (IQR) 0.33 (0.19)
Fundamental diagnosis, n (%)
  Atrioventricular canal defect 19 (28)
  Congenital mitral stenosis 12 (18)
  Mitral regurgitation (congenital or acquired) 5 (7)
  Congenital mitral regurgitation and mitral stenosis 19 (28)
  Shone syndrome/complex 5 (7)
  Hypoplastic left heart syndrome 3 (4)
  Tricuspid regurgitation 2 (3)
  Pulmonary atresia with intact ventricular septum 2 (3)
  Native MV endocarditis 1 (1)
Comorbidities, n (%)
  Heterotaxy syndrome 3 (4)
  Trisomy 21 3 (4)
  Other genetic syndromes 5 (7)
Previous valve repair or replacement, n (%) 49 (72)
  1 previous valve surgery, n 30
  ≥2 previous valve surgeries, n 19
Previously implanted prosthetic valve degeneration, n (%) 6 (9)
ASD indicates atrial septal defect; BSA, body surface area; IQR, interquartile 
range; and SVD, structural valve deterioration.
Table 2. Operative Techniques for Surgical Implantation of the 
Melody Valve With Postoperative Gradients and Long-Term Outcomes
Variables
Total 
(n=68)
Mitral 
(n=59)
Tricuspid 
(n=9)
Melody valve modification, n (%) 62 (91) 55 (93) 7 (78)
V shape, n (%) 13 (19) 13 (22) 0
Melody stent trimmed (distal), 
n (%)
26 (38) 22 (37) 4 (44)
Melody stent trimmed (proximal), 
n (%)
42 (62) 35 (59) 7 (78)
Addition of pericardial skirt, n (%) 42 (62) 38 (64) 4 (44)
Implanted with running sutures, 
n (%)
33 (48) 28 (47) 5 (55)
Implanted with interrupted 
sutures, n (%)
36 (53) 33 (56) 3 (33)
ASD creation, n (%) 17 (25) 17 (29) 0
Attachment to the free wall, n (%) 21 (31) 21 (35) 0
Balloon dilation size, mm; 
median (IQR)
14 (15) 14 (15) 16 (10)
Discharge gradient, mm Hg; 
median (range)
4 (0–16) 4 (2–7) 5 (1–9)
Discharge regurgitation grade, 
median (range)
None (none-
trivial)
None (none-
trivial)
None 
(none-mild)
Heart block, n (%) 10 (15) 8 (13) 2 (22)
Mortality, n (%) 15 (22) 11 (19) 4 (44)
  In-hospital death, n (%) 8 (12) 7 (12) 1 (11)
  Late death, n (%) 7 (10) 4 (8) 3 (33)
Cardiac transplantation, n (%) 3 (4) 2 (33) 1 (11)
Cardiac catheterization, total 
procedure, n (%)
41 (60) 2 (3) 1 (11)
1 cardiac catheterization 
procedure
25 (37) 24 (41) 1 (11)
 ≥2 cardiac catheterization 
procedures
16 (23) 16 (27) 0
SVD and valve re-replacement 19 (36) 17 (35) 2 (40)
ASD indicates atrial septal defect; and SVD, structural valve deterioration.
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The median duration of hospitalization was 21 days 
(range, 6–722 days).
At discharge, the mean echocardiographic Doppler 
gradient of the Melody in mitral position was 4 mm Hg 
(interquartile range, 5 mm Hg; full range, 0–16 mm Hg), 
and regurgitation was mild or less in 54 (98%) patients. 
The median value of the mean gradient of the Melody 
valve in tricuspid position at discharge was 5 mm Hg 
(interquartile range, 8 mm Hg; full range, 0–12 mm Hg), 
and regurgitation was mild or less in 8 (86%) patients 
(Table 2).
The mean follow-up time was 23 months (range, 2 
days to 4.7 years) for the entire cohort.
The Kaplan-Meier estimated freedom from mortal-
ity or OHT was 81% (70%–89%) at 6 months, 76% 
(63%–85%) at 12 months, and 72% (58%–81%) at 
24 months (Figure 2).
In total, 15 deaths occurred, including 11 in patients 
who underwent MVR (8 in-hospital and 3 late deaths) 
and 4 in those who underwent tricuspid valve replace-
ment (all late deaths). Six of the 15 deaths occurred in 
patients receiving extracorporeal membrane oxygen-
ation assistance for severe ventricular dysfunction. In 
these cases, the Melody valve was successfully implanted 
as salvage therapy in critically ill patients; however, only 
1 of them recovered, whereas 6 died from multiorgan 
failure, despite having a functional valve prosthesis. 
Three patients (mitral, n=2; tricuspid, n=1) underwent 
OHT at 2, 3, and 3.8 months after Melody valve implan-
tation. In each of these patients, transplantation was the 
intended long-term therapy, and valve replacement was 
performed as a bridge to planned transplantation.
The median gradient of the Melody valve on the 
most recent follow-up echocardiogram was 7.5 
mm Hg (interquartile range, 17 mm Hg; full range, 
0–22 mm Hg), and regurgitation was mild or less in 
82% of the patients. As gradients were measured 
only at the most recent follow-up, as opposed to mul-
tiple testing points, trends could not be assessed over 
time. Nineteen (28%) patients, 17 in the mitral posi-
tion and 2 in the tricuspid position, showed clinically 
worsened valvar regurgitation (moderate or severe) 
during follow-up. All but 2 had extensive valve modi-
fication (V shape in 4 patients, trimming or bending in 
12 patients, and skirt addiction in 11 patients). Gray 
test of difference showed no evidence of correlation 
between adverse events (SVD or valve replacement, 
and mortality or OHT) and surgical implantation tech-
niques, such as resection of the valve stent and graft 
(proximal, distal, and sinus facing the LVOT), or type of 
sutures performed.
During follow-up, a subgroup of 25 (37%) patients 
(mitral, n=24; tricuspid, n=1) with increasing transval-
vular gradient underwent balloon dilation for expansion 
of the Melody valve. The median time to first balloon 
dilation was 6.9 months after implantation (range, 7 
days to 2.8 years). Ten patients with Melody in mitral 
position had >1 balloon dilation, for a total of 41 pro-
cedures. After cardiac catheterization, median transval-
vular gradient decreased significantly from before to 
after balloon dilation (Wilcoxon rank-sum test, P<0.05; 
Figure 3A). The grade of valvular regurgitation was not 
significantly different before and immediately after bal-
loon dilation (Figure 3B).
Reoperation was performed in 19 (32%) patients, 
including 16 patients (all MVR) who underwent valve 
re-replacement. Reasons for valve re-replacement were 
endocarditis in 2 patients, SVD without evidence of 
endocarditis or blood stream infection in 6, Melody 
valve stenosis in 2, stent fracture in 2, and perivalvular 
leak in 1 patient.
Nonexplantation cardiac reoperations were per-
formed in 3 patients, including 1 patient who under-
went reoperation for relief of LVOT obstruction that 
developed after valve implantation, 1 patient who 
underwent epicardial pacemaker leads implantation, 
and 1 patient who underwent surgical closure of a 
paravalvular leak. Transient obstruction occurred imme-
diately after the procedure in 7 (10%) patients second-
ary to the protruding stent. However, LVOT obstruction 
improved over time in 5, and only 2 (3%) patients 
required subaortic membrane resection. In 2 patients 
with LVOT obstruction, tilting of the distal portion of 
the Melody valve stent into the outflow tract contrib-
uted to obstruction and resulted in catheter-based 
interventions followed by reoperation. In 1 patient, the 
valve was eventually replaced; in the other, the Melody 
valve was expanded through a balloon catheter during 
surgery to relieve LVOT obstruction,
In 4 patients who developed central regurgitation 
and underwent Melody valve explantation, the valve 
showed perforation in one of the leaflets on surgical 
inspection (Figure 4). One of these patients developed 
central regurgitation 5 months after implantation, 
and on gross surgical examination, an injury related 
Figure 2. Kaplan-Meier curve with 2-sided 95% CIs depicting freedom 
from mortality or orthotopic heart transplantation (OHT).
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to suture placement at the time of implantation was 
suspected. Another patient was lost at follow-up and 
was readmitted to the hospital with severe SVD. In 
this child, the histological examination of the valve 
showed signs of leaflet calcification and inflammation 
suggesting suspected endocarditis. In the remaining 2 
patients, the degeneration of the valve was unknown 
because history and signs of endocarditis were not 
found. Leaflet morphology and histology examined in 
3 of those 4 patients undergoing valve excision at 3, 
12,17 and 26 months after implantation demonstrated 
thin leaflets without evidence of leaflet calcification or 
inflammation.
In 1 patient, who died 13 months after Melody valve 
implantation because of an acute septicemia most 
probably not related to endocarditis, the valve was sta-
ble with only mild regurgitation without any relevant 
inflow gradient on echocardiogram. Histopathologic 
workup demonstrated complete neoendothelializa-
tion and only little neointimal formation, no signs of 
calcification, and loosely inflammatory reactions with 
no macrophages or granulocytes confirming the good 
biocompatibility of the valve.23
Competing Risks Analyses
Within 2 years after Melody valve implantation, the 
crude cumulative incidence of death as first event was 
28% (17%–39%; Figure 5A), whereas the crude cumu-
lative incidence of valve re-replacement or SVD as first 
event was 20% (11%–32%; Figure 5B).
Considering Melody SVD or valve explantation and 
mortality or OHT as competing events, the estimated 
probability of experiencing one of the adverse events is 
28% (18%–40%) during the first year and 45% (32%–
58%) within 2 years after Melody valve implantation 
(Figure  5C). The highest incidence of adverse events 
was in the first month after the procedure and is mostly 
comprised of death (Figure 5C).
Regarding cardiac catheterization, the estimated 
crude cumulative incidence was 17% (8%–27%) at 
6 months, 18% (10%–29%) at 12 months, and 23% 
(13%–35%) at 24 months (Figure 6).
DISCUSSION
This study presents a multi-institutional experience with 
feasibility, safety, and clinical efficacy of the surgical 
Figure 3. Transvalvular gradient and regurgitation immediately before and after balloon dilation of the valve.  
A significant reduction in transvalvular gradient is seen (P<0.001; A). The grade of regurgitation was not significantly different before and immediately after balloon dilation (B).
Figure 4. Gross examination of an explanted Melody valve from a patient 26 mo after implantation in the mitral position.  
Follow-up echocardiogram showed abnormal prolapse of 1 leaflet of the Melody valve (A, white arrow) conditioning massive valve regurgitation (B). The explanted 
valve showed injury to leaflet (C, black arrow) with thin leaflets and no evidence of inflammation or calcification.
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implantation of the Melody valve in the atrioventricular 
position for the treatment of dysfunctional atrioventric-
ular valve in pediatric patients with hypoplastic annuli. 
The results indicate that there is a high rate of procedural 
success but high mortality in patients supported with 
extracorporeal membrane oxygenation. Medium-term 
follow-up showed that the Melody valve can be effec-
tively balloon expanded to account for patient somatic 
growth. However, SVD and need for reoperation remain 
significant challenges with the current design.
Despite the significant advances in the management 
and treatment of complex congenital heart defects, 
surgical repair of atrioventricular valve dysfunction in 
children still carries a high mortality risk.1–3 In the pedi-
atric population, valve repair surgery is preferred and 
feasible in most patients; however, in patients with 
irreparable atrioventricular valves, valve replacement is 
the only option.
There are numerous concerns associated with pros-
thetic valve replacement in children. First, the small 
atrioventricular annulus in children limits the prosthetic 
options, considering that available prostheses range 
from 15 to 27 mm in diameter. Second, the growth of 
the atrioventricular annulus at small ages is exponential, 
Figure 5. Estimated cumulative incidence 
curves with 2-sided 95% CIs.  
A, Mortality or orthotopic heart transplantation. 
B, Structural valve deterioration or valve replace-
ment. C, The combination of these 3 events.
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and a fixed-sized prosthesis cannot accommodate for 
somatic growth of the patient. Thus, children who 
undergo valve replacement at a younger age require 
early reoperation to upsize the valve. Whereas biopros-
theses tend to degenerate rapidly in young patients, 
mechanical prostheses require anticoagulation, which 
can be difficult to regulate in children.24
In this setting, the concept of an expandable pros-
thetic valve is appealing. Conceived as a temporary 
device to replace failing pulmonary valves, the Melody 
valve has shown adequate performance even under 
systemic pressures encountered in pulmonary hyperten-
sion.25 In recent years, it has been used in a small cohort 
of pediatric patients for the treatment of dysfunctional 
mitral valves with promising results.16,19,26 Feature that 
makes the stented bovine jugular vein graft optimal 
for valve replacement in children is the redundancy of 
the valve leaflets, which allows coaptation to occur on 
a range of diameters between 10 and 22 mm. After 
implantation at a small diameter, the valve may be sub-
sequently balloon expanded by cardiac catheterization 
as the patient grows, thus delaying the need for reoper-
ation. The thin stent structure minimizes the difference 
between the external support and internal diameter 
thus optimizing the effective valve orifice area.27
In the current cohort of patients, Melody valve 
implantation significantly improved inflow obstruction 
and valve regurgitation. Improvement in regurgitation 
has been shown to correlate with better outcomes espe-
cially after mitral valve surgery in children.28 However, a 
significant number developed SVD of the Melody valve 
and required reoperation at median of 22 months after 
implantation. The underlying cause of SVD included 
endocarditis, paravalvular leak, and central valvular 
regurgitation because of leaflet perforation or nonco-
aptation. Although valve modification techniques were 
not statistically significantly associated with SVD, it is 
possible that surgical manipulation of the valve contrib-
uted to SVD. And because of this, it is ideal to avoid 
modifications to the valve when possible. However, 
in some cases of patients with small valve annuli, the 
inclusion of modifications (such as the deep V cut or 
trimming of the stent) is necessary to avoid left ventric-
ular outflow tract obstruction. Because the valve is not 
designed for surgical implantation, paravalvular leak at 
the interface between the stent and annulus may occur. 
Improvements in valve implantation technique occurred 
during the course of the study, leading to reduction 
in the rates of SVD over time. Improvements in valve 
design, specifically tailored for surgical implantation, 
may further decrease the incidence of SVD.
Endocarditis has been reported after transcatheter 
Melody valve implantation.29 In our cohort, endocar-
ditis or blood stream infection was documented only 
in 2 patients. However, in case of SVD, a high index 
of suspicion for infective endocarditis should be always 
raised. Patients should be advised to follow lifelong 
antibiotic prophylaxis before surgical or dental proce-
dures, and surgical management should not be delayed 
after Melody valve dysfunction.
Inflammation or calcification has been noted in 
explanted Melody valves, primarily demonstrated as 
pannus formation on the vein graft outer wall. However, 
remarkably, there is limited involvement of the leaflets 
in general, and they remain pliable for a significant span 
of time. The leaflets seem to be somewhat protected by 
the vein wall graft, which shields the internal leaflets. It 
is rare but certainly possible to develop pannus on the 
leaflets, and they can in fact develop a fibrous film as 
in the case with other bioprostheses. Because of the 
potential fibrotic response of utilizing a xenograft, the 
Melody valve is not intended to be a lifelong solution. 
Importantly, these explanted valves represent the select 
group of patients with valve failure.
Considering mortality, valve replacement, and car-
diac catheterization as adverse events during follow-up, 
the highest incidence of adverse events occurred dur-
ing the first month after surgery and was mostly com-
prised of death. All but one of the early deaths occurred 
in patients who required perioperative extracorporeal 
membrane oxygenation assistance because of ventric-
ular dysfunction, despite the technical success of the 
procedure. Patients with late mortality exhibited various 
combinations of complex congenital heart defect, ven-
tricular noncompliance, arrhythmias, and pulmonary 
hypertension. Valve disease in children and infants is 
a marker for underlying cardiac comorbidity, and this 
study demonstrates that valve replacement alone may 
not be sufficient to alleviate cardiac-related mortality in 
this population.
Timing of atrioventricular valve replacement in pedi-
atric patients is highly variable and may impact sur-
vival.2,7 Given the current prosthetic options for valve 
replacement, clinicians may medically manage young 
patients with significant valvular disease, resorting to 
Figure 6. Estimated cumulative incidence curves with 2-sided 95% 
CIs of cardiac catheterization as first events in those who survived 
surgery.
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surgery only after progressive clinical deterioration. It 
can be speculated that in these patients, earlier sur-
gical replacement might have mitigated the severity 
of dysfunction and improved survival. The availability 
of a durable expandable valve may allow clinicians 
to intervene earlier in the clinical course, before the 
development of irreversible injury. The need for valve 
replacement may also be a marker for ventricular non-
compliance and dysfunction, which are not altered by 
valve replacement alone.
The ideal candidate for Melody valve in the atrio-
ventricular valve position is the patient with irrepa-
rable atrioventricular valve and annular size <15 mm. 
The goal of valve replacement with Melody valve is to 
provide valvular competence until a child can receive a 
traditional prosthesis (>19 mm), by serial dilation over 
time. Many of the patients in this study who underwent 
repeat replacement late after Melody valve implantation 
were able to receive traditional prosthesis. Based on the 
durability data presented in this study, it is unlikely that 
the Melody valve will last until adulthood. Given the cur-
rently available options for bioprosthetic and mechani-
cal valve replacement, we cannot recommend use of the 
Melody valve for patients with annulus size >19 mm. For 
patients with annuli between 15 and 19 mm, another 
option for atrioventricular replacement is 15 or 17 mm 
mechanical prosthesis or supra-annular implantation 
of larger mechanical valves. However, increased risk of 
atrial noncompliance and valve thrombosis has been 
reported with supra-annular implantation.7 Future stud-
ies are necessary to compare the durability of Melody 
valve with 16 or 17 mm mechanical valves.
Considering that in 9% of our patients the indication 
for Melody valve replacement was mechanical valve 
dysfunction, Melody valve should be contemplated 
also as a bailout option for mechanical valve throm-
bosis that is in patients with hypercoagulability states 
or bleeding issue under anticoagulation. Current rec-
ommendations for anticoagulation after Melody valve 
replacement have not yet been validated but based on 
previous studies suggesting low risk of thromboem-
bolic events at short-term follow-up alone is currently 
recommended.17 Long-term data on thromboembolic 
complications, such as stroke and limb ischemia, will be 
necessary to determine optimal therapy.
Optimal valve sizing of the Melody valve at the time 
of implantation has yet to be established. The protocol 
for implantation followed by participating centers was 
based on previous experience.30 None of the patients 
sustained coronary artery damage, and only 1 (1.5%) 
patient developed complete heart block requiring 
pacemaker implantation. This incidence of heart block 
is lower than previously reported with mitral annulus 
upsizing in children,31 highlighting the potential benefit 
of the Melody valve that can be dilated after somatic 
growth of patients. However, cardiac catheterization 
is not free of adverse events, and the risk of coronary 
artery injury, heart block, and left ventricular outflow 
tract obstruction associated with excessive valve dila-
tion at the time of surgery must be weighed against 
the need for early catheterization associated with less-
aggressive expansion.
The Melody valve stent is ≈28 mm long, which occu-
pies significant space within the atrial and ventricular 
chambers and may potentially result in obstruction of 
the venous return or ventricular outflow tract. To prevent 
these complications, most of the centers modified the 
valve by either stent trimming or folding. In this series, 
inflow and outflow tract obstruction after Melody valve 
placement was a rare occurrence. No direct relationship 
was found between Melody valve failure and valve modi-
fication at implantation. However, it should be taken into 
account that excessive valve modification can be respon-
sible for SVD during the follow-up. In particular, stent 
fractures remain the most common reason for reinterven-
tion with the Melody valve in pulmonary position because 
they are associated with early conduit restenosis and valve 
failure.26 In our series, documented mechanisms of SVD 
in patients who underwent valve re-replacement included 
damage of the thin conduit wall during valve prepara-
tion, surgical injury of a valve leaflet during the valve 
modification, and penetration of the valve leaflets dur-
ing balloon-catheter expansion of the prosthesis. Further 
customization of valve design for surgical atrioventricular 
valve replacement may reduce the need for valve modifi-
cations and thereby improve durability.
The median interval between surgery and the first 
catheter-based dilation was ≈6.5 months. It is impor-
tant to note that because the gradient measured by 
echocardiography can differ from the gradient mea-
sured by catheterization, thus change in the echo-
cardiographic gradient rather than a threshold value 
should be used to determine the timing of catheteriza-
tion. Catheter-based dilation was well tolerated in most 
patients without development of more that mild regur-
gitation. The results demonstrate that valve expansion 
after somatic growth is feasible, allows relief of gradi-
ent across the valve, and delays reoperation for repeat 
valve replacement.
CONCLUSIONS
Although the mortality and adverse event profile for 
Melody valve placement in the atrioventricular valve 
position in pediatric patients is similar to other valve 
alternatives, there remain many potential benefits to this 
technology. First, the valve may be tailored to annuli that 
are too small for currently available prostheses avoiding 
supra-annular placement. Next, the Melody valve may 
be expanded in the catheterization laboratory to accom-
modate somatic growth thus avoiding repeat surgery. 
Finally, it avoids the complexity of anticoagulation in 
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small children and the associated complications of anti-
coagulation. Despite these things, many of the patients 
in this cohort were implanted with the Melody valve as 
a salvage therapy, thus there are still some noted nega-
tive outcomes (ie, risk of endocarditis) and an overall 
mortality of 22%. Perhaps the risk can be reduced if 
the valve is replaced sooner. Although further studies 
are needed to optimize patient selection, future design 
modifications are necessary to improve durability and 
expand applicability to the most challenging patients.
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